These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Association of the CCR5delta32 mutation with improved response to antiretroviral therapy. Valdez H; Purvis SF; Lederman MM; Fillingame M; Zimmerman PA JAMA; 1999 Aug; 282(8):734. PubMed ID: 10463706 [No Abstract] [Full Text] [Related]
43. HIV drug-resistance testing on archived samples to help current clinical decisions. Dean GL; Fisher M; Loveday C AIDS; 2000 Jan; 14(2):208-9. PubMed ID: 10708296 [No Abstract] [Full Text] [Related]
44. A multicentre cohort experience with double-boosted protease inhibitors. Stebbing J; Scourfield A; Koh G; Taylor C; Taylor S; Wilkins E; Gazzard B; Nelson M; Jones R J Antimicrob Chemother; 2009 Aug; 64(2):434-5. PubMed ID: 19474068 [No Abstract] [Full Text] [Related]
45. A predominance of R5-like HIV genotypes in vaginal secretions is associated with elevated plasma HIV-1 RNA levels and the absence of anti-retroviral therapy. Randolph TC; Kissinger PJ; Clark RA; Lacour N; Amedee AM Virol J; 2008 Jul; 5():87. PubMed ID: 18664290 [TBL] [Abstract][Full Text] [Related]
46. What's all this stuff about "logs?" The low-down on reading the PCR test. PI Perspect; 1995 Dec; (no 17):15-6. PubMed ID: 11363107 [TBL] [Abstract][Full Text] [Related]
48. Therapy-resistant opsoclonus-myoclonus syndrome secondary to HIV-1 infection. Wiersinga WJ; Prins JM; van de Beek D Clin Infect Dis; 2012 Feb; 54(3):447-8. PubMed ID: 22247305 [No Abstract] [Full Text] [Related]
49. High, low, and very low viral loads of HIV in the United States. Peter JB J Acquir Immune Defic Syndr; 2000 May; 24(1):83-4. PubMed ID: 10877503 [No Abstract] [Full Text] [Related]
50. Not all is dead in HIV-1 graveyard. Grant RM; Abrams DI Lancet; 1998 Jan; 351(9099):308-9. PubMed ID: 9652607 [No Abstract] [Full Text] [Related]
55. Concentration-targeted therapy and the future of HIV management. Flexner CW; Piscitelli SC AIDS; 2002 Mar; 16 Suppl 1():S1-3. PubMed ID: 12035819 [No Abstract] [Full Text] [Related]
56. Combination antiretroviral therapy including a protease inhibitor eliminated the transfusion requirements of HIV-infected individuals with anemia of chronic disease. Mylonakis E; Dickinson B; Feller A; Sweeney J; Schiffman FJ; Rich J; Flanigan T J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):306-7. PubMed ID: 9803974 [No Abstract] [Full Text] [Related]
57. Reconceptualizing research on HIV treatment outcomes among criminalized groups. Carrieri MP; Wolfe D; Roux P J Acquir Immune Defic Syndr; 2012 Apr; 59(4):329-30. PubMed ID: 22134150 [No Abstract] [Full Text] [Related]
58. HIV-proteinase inhibitors in the management of HIV-infection. Moyle GJ; Barton SE J Antimicrob Chemother; 1996 Dec; 38(6):921-5. PubMed ID: 9023639 [No Abstract] [Full Text] [Related]
59. Factors influencing combination antiretroviral therapy choice: Do doctors really know best? Hata M; Redlin SE; Nelson M J Infect; 2015 Aug; 71(2):269-71. PubMed ID: 25818533 [No Abstract] [Full Text] [Related]
60. Does the presence of a mutation at position V179 impact on virological outcome in patients receiving antiretroviral medication? Vink J; McFaul K; Bradshaw D; Nelson M J Infect; 2016 May; 72(5):632-3. PubMed ID: 26979379 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]